Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.
- Conditions
- Lung Cancer
- Registration Number
- NCT06376097
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br>Age between 45 and 74 years old; Smoker with a smoking history of at least 30 pack-years<br>or former smoker who has quit smoking for less than 15 years; Never having participated<br>in a lung cancer screening program; Signing of the free and informed consent form.<br><br>Exclusion Criteria:<br><br>Patients with chronic diseases (cardiovascular, pulmonary, hepatic, renal or metabolic)<br>at an advanced stage that limit life expectancy or make it impossible to perform a<br>curative surgical procedure; Patients being treated for tuberculosis or other<br>granulomatous diseases; Patients diagnosed with previous neoplasm(s) that could develop<br>lung metastases; Pregnant women; Patients who, for some reason, are unable to undergo<br>low-dose chest computed tomography; Patients previously submitted to thoracic<br>radiotherapy.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Absolute number and frequency of false-negative lung nodules .
- Secondary Outcome Measures
Name Time Method Assess adherence to smoking cessation treatment in active smokers who enter screening.;Assessment of morbidity and mortality in patients undergoing invasive procedures, whether diagnostic or therapeutic.;Cost comparasion of treating patients in metastatic setting vs. treating early-stage lung cancer patients, including all costs from the screening program.